EDGE Unveils First UAE-made Family of Smart Loitering Munitions at IDEX 2021
21.2.2021 19:08:00 EET | Business Wire | Press release
EDGE, an advanced technology group for defence and beyond, today launches its first family of multirotor loitering munitions, the QX range. In addition, Shadow 50 and Shadow 25, Rash 2 gliding munition kit, as well as new variants of the RW24 range – all designed and manufactured in the company’s first year of operations – were unveiled on the first day of the International Defence Exhibition and Conference (IDEX 2021), that is underway at the Abu Dhabi National Exhibition Centre until 25 February.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210221005030/en/
EDGE launches QX range- its first family of multirotor loitering munitions (Photo: AETOSWire)
The unveiling of the Class-1 electric unmanned aerial vehicles (UAVs) took place at the EDGE pavilion in the presence of His Excellency Faisal Al Bannai, CEO and Managing Director of EDGE and Ali Al Yafei, CEO of ADASI.
His Excellency Faisal Al Bannai, CEO & Managing Director, EDGE, said: “Right now, drone technology is revolutionising our world with the full potential of unmanned and autonomous capabilities still to be further explored – not just in the military sector, but the commercial sector too.”
He added: “Through launching the first UAE-made family of smart loitering drones, EDGE marks a significant milestone as a key technology enabler and in boosting the country’s autonomous capabilities and AI integration. With the future increasingly relying on unmanned systems that provide a higher degree of tactical flexibility, we have invested extensively to fast-track R&D investments in these domains, bringing related products to market with speed.”
The QX family of loitering munitions comprises four products: QX-1, a micro-UAV, QX-2, a mini-UAV, QX-3, a small UAV, and QX-4, which features an impressive vertical take-off and landing (VTOL) fixed wing. The precision-guided systems use sophisticated AI algorithms to target and strike, boasting an accuracy of 1 m CEP (circular error probable) – with an aim similar to laser guided munitions. Built to launch in any environment or terrain, the entire QX family of UAVs are lightweight, man portable, and comprise VTOL capabilities.
The second range of loitering munitions consists of Shadow 50 and Shadow 25. As the name implies, Shadow 50 can carry a payload of 50kg – exactly double its counterpart. Shadow 25 is a high-speed system equipped with a jet engine and boasts a short reaction time. Delivering high precision strike against fixed targets and advanced guidance capabilities, these UAVs leverage Global Navigation Satellite Systems (GNSS) and can fly using video navigation systems in GPS denied Environment.
Also launched on Day 1 of IDEX, the Rash 2 is a fixed-wing guidance kit for mortars and other in-house designed payloads, capable of gliding in flight and directing munitions to ground targets, available in different sizes to accommodate varying payload capacity, range, and endurance. ADASI has secured AED 55 million contract to supply Rash 2 to the UAE Armed Forces, marking the first order of the newly launched product.
Three new additions to the RW-24 range were also launched in time for IDEX 2021. The newly unveiled RW-24 Seeker is equipped with a thermal automatic seeker that enable greater accuracy of engagement of moving targets and increased functionality within GPS-denied environments.
The RW-24 Extended Warhead and RW-24 Extended Range variants increase the payload capacity from 8 kg to 13 kg, enabling the drone to carry additional fuel or to increase the size of the warhead.
EDGE is an advanced technology group that ranks among the top 25 military suppliers in the world.
About EDGE
EDGE is an advanced technology group established to develop agile, bold and disruptive solutions for defence and beyond. Enabling a secure future, it is dedicated to bringing innovative technologies and services to market with greater speed and efficiency. Consolidating over 25 entities and employing more than 13,000 brilliant minds, it offers expertise across five core clusters: Platforms & Systems, Missiles & Weapons, Cyber Defence, Electronic Warfare & Intelligence and Mission Support. Headquartered in Abu Dhabi, United Arab Emirates, EDGE is a catalyst for change – set to revolutionise the industry and change its fundamentals.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210221005030/en/
Contact information
Thushara Mohanan
media@edgegroup.ae
+971-555080413/ +971-55-3584520
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom